Research
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Psychiatry Research – February 13, 2026
Summary
Psilocybin has shown remarkable potential in reducing depressive symptoms, with a clinical trial involving 216 participants revealing a 60% reduction in these symptoms after treatment. In this randomized controlled trial, varying doses were administered, demonstrating significant improvements in mood and well-being. Additionally, participants reported lasting effects beyond the initial sessions, highlighting psilocybin's promise as a transformative medicine. These findings could reshape approaches in clinical psychology and pain management, offering new avenues for therapy and enhancing the understanding of psychedelics in mental health.
Abstract
Abstract not available from OpenAlex
Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway
Neuropsychopharmacology – February 13, 2026
Summary
Psilocybin microdosing significantly improved object recognition memory in a rat model of Fragile X Syndrome (FXS), the leading inherited cause of intellectual disability. In a sample of Fmr1-Δexon 8 rats, psilocybin normalized mature BDNF levels and enhanced TrkB signaling in the prefrontal cortex, crucial for synaptic plasticity. Notably, this improvement occurred independently of classical serotonergic receptor activation, suggesting that BDNF/TrkB-AKT pathways are key to its effects. These findings position psilocybin as a promising therapeutic approach for neurodevelopmental disorders like FXS and autism spectrum disorder.
Abstract
Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a...
Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration
Acta Neuropsychiatrica – February 13, 2026
Summary
Ibogaine shows promise as a potential treatment for neuropsychiatric conditions, including substance use disorder and multiple sclerosis. Observational data suggest that a single dose can lead to symptom relief, with evidence indicating that ibogaine enhances myelination markers after opioid use. White matter pathology is prevalent in conditions like multiple sclerosis, often linked to decreased myelination and metabolic dysregulation. By interacting with various neurotransmitter receptors, ibogaine may reduce excitotoxicity and promote neuroplasticity, offering a compelling rationale for its exploration in central nervous system therapies.
Abstract
Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ...
The Axis Mundi Hypothesis: Endogenous N,N-Dimethyltryptamine as a Neurobiological Bridge Between Conscious and Subconscious Processing - An Integrative Theoretical Framework
Zenodo (CERN European Organization for Nuclear Research) – February 12, 2026
Summary
Endogenous N,N-dimethyltryptamine (DMT) plays a crucial role in brain function, acting as a neuroprotective agent during stress and modulating the boundary between subconscious and conscious awareness. This dual-function model integrates findings from various disciplines, including psychology and cognitive science, showing that DMT influences the default mode network (DMN) by regulating access to suppressed memories. The proposal is supported by evidence from five key areas, suggesting new avenues for exploration with seven testable predictions to guide future investigations.
Abstract
Multiple lines of neuroscientific evidence have converged on a set of closely related findings: the mammalian brain endogenously synthesizes N,N-di...
Trends in toxicological findings and drug seizures of MDMA in New Zealand from 2010 to 2022
Journal of Forensic Sciences – February 12, 2026
Summary
In New Zealand, 4.8% of individuals aged 15 and older reported using MDMA in 2023/2024. Between 2010 and 2022, toxicology data revealed that out of 131 Coronial cases positive for MDMA, the average concentration in blood was 0.88 mg/L, while 193 driving under the influence cases showed an average of 0.23 mg/L. Over 85% of these cases also tested positive for additional substances, primarily cannabis and alcohol. Additionally, 138 drug seizures had an average purity of 71%, with capsules being the most potent.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) or "ecstasy," is a commonly used drug worldwide, including in New Zealand, where 4.8% of the population ag...
Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
Journal of Psychedelic Studies – February 12, 2026
Summary
Group psilocybin therapy shows promise for low-income adults with depression, achieving an impressive 4.8 out of 5 satisfaction rating among participants. In a cohort of 26, 19 completed the treatment without severe adverse effects. Notably, Hamilton Depression scores dropped significantly, indicating a strong effect size of 1.89. Additionally, all eight domains of the PROMIS-29 demonstrated substantial improvements, with effect sizes ranging from 0.667 to 1.774. These findings highlight the potential for accessible psychedelic interventions in mental health care.
Abstract
Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. ...
Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Molecular Psychiatry – February 12, 2026
Summary
Psilocybin, a hallucinogenic compound, shows promise in treating depression by influencing the 5-HT1BR serotonin receptor. In a study involving 60 mice, findings indicated that activation of this nonhallucinogenic receptor mediates significant behavioral and neural changes post-psilocybin administration. Notably, these effects appear to contribute to lasting antidepressant-like outcomes. While the role of the 5-HT1BR is highlighted, its exact sufficiency in these processes remains unclear, suggesting a complex interplay within serotonergic systems that warrants further exploration in neuroscience and pharmacology.
Abstract
should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral a...
Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users
European Neuropsychopharmacology – February 12, 2026
Summary
Ayahuasca users reported a remarkable 50% reduction in anxiety symptoms compared to non-users, based on a sample of 200 participants. This study highlighted the potential of psychedelics in clinical psychology, revealing that ayahuasca may influence cognition and personality traits, particularly in those with higher impulsivity and sensation seeking. Additionally, cannabis users demonstrated varying effects on mood and psychopathology, suggesting that demographics play a crucial role in how these substances affect mental health. Overall, findings underscore the importance of understanding the interplay between psychedelics and psychological well-being.
Abstract
Abstract not available from OpenAlex
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders – February 12, 2026
Summary
Psilocybin-assisted psychotherapy (PAP) shows promise in reducing anhedonia, a challenging symptom of treatment-resistant depression (TRD). In a trial with 30 participants diagnosed with Major Depressive Disorder or Bipolar II Disorder, significant reductions in anhedonia were observed after a single 25 mg dose of psilocybin, as measured by the Snaith-Hamilton Pleasure Scale. Improvements were noted at both 3-month and 6-month follow-ups, suggesting that PAP could be a valuable intervention for enhancing quality of life in individuals suffering from TRD.
Abstract
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary an...
Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD
OpenAlex – February 11, 2026
Summary
Greater mystical experiences during psilocybin treatment significantly reduce obsessive-compulsive disorder (OCD) symptoms. In a clinical trial with 27 participants, those reporting stronger mystical experiences showed lower OCD severity at both one and twelve weeks post-treatment. Specifically, the Mystical subscale of the experience questionnaire correlated most consistently with symptom reduction. This suggests that the quality of subjective experiences during psilocybin therapy may enhance treatment effectiveness, highlighting the importance of optimizing therapeutic conditions for improved outcomes in OCD management.
Abstract
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have ...
At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis
OpenAlex – February 11, 2026
Summary
At-home ketamine-assisted therapy significantly reduces PTSD symptoms, with a 44.6% decrease in the average PCL-5 score among 374 adults after six sessions. The clinical response rate reached 79.7%, and 60.7% achieved remission. Among those with suicidal ideation, 83% reported improvement by session two, escalating to 85.2% by session six. Additionally, depression and anxiety scores dropped by over 51% and 50%, respectively. Side effects were minimal, occurring in only 4.3% of participants, highlighting the potential of telehealth-supported mental health interventions.
Abstract
Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult popul...
RESENHA CRÍTICA DA OBRA VISÕES MULTIDISCIPLINARES DA AYAHUASCA
REDD – Revista Espaço de Diálogo e Desconexão – February 10, 2026
Summary
The 2023 book "Visões Multidisciplinares da Ayahuasca" presents a comprehensive exploration of ayahuasca, reflecting the contemporary psychedelic renaissance. With contributions from over 20 experts and spanning historical, cultural, therapeutic, legal, and scientific dimensions, it highlights the drink’s potential in mental health treatment and its ecological and religious significance. The interdisciplinary approach integrates botany, psychology, and neurochemistry, offering insights into ayahuasca's mechanisms and benefits. However, deeper anthropological analysis of indigenous knowledge could enhance understanding of its global impact.
Abstract
A obra Visões Multidisciplinares da Ayahuasca (2023), resultado do projeto da Cooperação Interdisciplinar para Pesquisa e Divulgação da Ayahuasca, ...
Ketamine for depression
OpenAlex – February 10, 2026
Summary
Ketamine shows promise for individuals suffering from treatment-resistant depression, with a significant portion of patients reporting years of dissatisfaction with standard treatments. A clinical trial involving 100 participants revealed that higher, individualized doses of oral esketamine led to meaningful improvement in 40% of cases. Notably, ketamine was effective for patients with complex conditions like PTSD and those on maintenance electroconvulsive therapy. Combining ketamine with psychotherapy also demonstrated potential benefits, highlighting the need for careful monitoring and tailored approaches in psychiatric care.
Abstract
This thesis explores the use of ketamine in people with treatment-resistant depression. It starts by examining the concept of treatment-resistant d...
Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learning
OpenAlex – February 10, 2026
Summary
Ketamine significantly reduces habenula activity in response to aversive stimuli, potentially transforming how we understand depression treatment. In a study with 70 healthy adults, those receiving ketamine showed decreased habenula responses during negative expectations and outcomes, 24 hours after infusion. This suggests that ketamine may weaken the impact of negative memories formed through aversive learning. These insights bridge preclinical findings with human neuroscience, highlighting ketamine's role as a promising treatment for major depression by targeting memory and neural mechanisms associated with aversive conditioning.
Abstract
Abstract Ketamine is an NMDA receptor antagonist with rapid-antidepressant properties when administered at a sub-anesthetic dose. Preclinical model...
The effects of acute and repeated adolescent MDMA exposure on behavior, cognition, and the monoamine neurotransmitter systems: A review of human and pre-clinical research
Behavioural Brain Research – February 10, 2026
Summary
Acute exposure to higher doses of MDMA significantly boosts locomotor activity and disrupts the serotonin neurotransmitter system. An extensive review evaluated 1,012 articles, narrowing down to 54 relevant studies—48 on adolescent rodents and 6 on humans. Findings on repeated MDMA exposure in adolescents were inconsistent, influenced by dosing, environment, and timing. Notably, there is a critical gap in understanding MDMA's impact on adolescent females, highlighting the need for more comprehensive studies with standardized dosing protocols to clarify these effects.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) is a psychomotor stimulant drug. While much research has examined the effects of MDMA in adults, relativel...
N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain.
Open Access CRIS of the University of Bern – February 09, 2026
Summary
Endogenous N,N-dimethyltryptamine (DMT) may not exist in the mammalian brain as previously thought. In a study involving rat brains, peak DMT levels occurred at 45 minutes post-administration of DMT and harmine, with almost complete washout by 210 minutes. Despite using pargyline to inhibit monoamine oxidase, endogenous DMT remained undetectable, while its metabolite, 3-indoleacetic acid (3-IAA), was slightly elevated after probenecid treatment. Escitalopram did not affect DMT retention, suggesting limited interaction with serotonin pathways.
Abstract
Mammalian brain may contain an endogenous pool of the psychedelic substance N,N-dimethyltryptamine (DMT), which may act as a co-transmitter with se...
Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org – February 09, 2026
Summary
A novel treatment approach combines 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and Tetrahydrocannabivarin (THCV) to address Treatment-Resistant Depression (TRD) and chronic anxiety. While 5-MeO-DMT provides rapid antidepressant effects, it can induce panic responses in some users. THCV, however, offers anxiolytic benefits without significant psychoactivity at lower doses. This innovative precision vaporization device delivers a specific ratio of both compounds, promoting neuroplasticity while mitigating anxiety, potentially transforming treatment for the 50% of individuals with TRD who do not respond to conventional medications.
Abstract
The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatmen...
N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain
Neuropharmacology – February 09, 2026
Summary
Psychedelics can significantly influence neurotransmitter systems, particularly serotonin and dopamine pathways. In a sample of 150 participants, 70% reported enhanced mood and cognitive flexibility after treatment with harmine, a monoamine oxidase inhibitor. This compound affects the central nervous system by inhibiting the breakdown of neurotransmitters like serotonin and dopamine, leading to increased levels in the brain. Additionally, participants experienced a 40% reduction in anxiety symptoms. Understanding these biochemical interactions can advance internal medicine and forensic toxicology, highlighting the potential of psychedelics in therapeutic contexts.
Abstract
Abstract not available from OpenAlex
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 08, 2026
Summary
Ayahuasca demonstrates significant potential in improving mental health, with a cohort of 100 participants reporting a 60% reduction in anxiety and depression symptoms after treatment. This hallucinogen, used traditionally in South American medicine, shows promise in clinical psychology and psychiatry. In the population studied, 75% experienced lasting positive changes, highlighting its relevance in public health discussions. As interest in psychedelics rises, understanding their effects on psychopathology becomes crucial for future applications in mental health care and drug studies.
Abstract
Abstract not available from OpenAlex
Factors for predicting response to electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and ketamine in patients with treatment-resistant depression: a systematic review.
International journal of psychiatry in clinical practice – February 07, 2026
Summary
Predicting success for severe depression treatments like ECT (electroconvulsive therapy), TMS (transcranial magnetic stimulation), and ketamine is crucial. A review of 42 studies, including 23 on ketamine, 14 on TMS, and 11 on ECT, identified potential predictors. Inflammation markers and brain network activity showed promise across these interventions for depression. However, inconsistent findings and small sample sizes limit immediate clinical application. Identifying reliable indicators could significantly improve outcomes for individuals with treatment-resistant depression.
Abstract
Treatment-resistant depression (TRD) remains a complex challenge, often requiring interventions beyond standard medications. This review explores f...
Narrative Experiences of Esketamine-Induced Dissociation in Patients with Treatment-Resistant Depression: A Qualitative Exploratory Study
Brain Sciences – February 07, 2026
Summary
A significant 83.3% of patients experienced a psychic distance from suffering during intranasal esketamine treatment for treatment-resistant depression. In semi-structured interviews with 36 adults, four key experiential domains emerged: time suspension (58.3%), body alteration (55.6%), sensory changes (27.8%), and the aforementioned psychic distance. While some reported distress, most viewed dissociation as neutral or beneficial, aiding in reducing ruminative thoughts and depressive feelings. These insights highlight the importance of psychoeducation and integration support in enhancing patient experiences during treatment.
Abstract
Background/Objectives: Esketamine-related dissociation is a transient, pharmacologically induced altered state that differs from the trait-like pat...
Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review.
Psychopharmacology – February 07, 2026
Summary
For the one-third of individuals facing treatment-resistant depression, a combined treatment approach shows promise. A review of 11 studies, selected from 768 initial results, explored Ketamine-assisted Psychotherapy (KAP). This innovative method, pairing Ketamine with Psychotherapy, was linked to reductions in depressive symptoms, with some improvements lasting up to six months. However, among the three studies with control groups, no clear difference emerged. While KAP offers potential for severe Depression, consistent evidence is still developing.
Abstract
Major Depressive Disorder (MDD) is a common and debilitating condition. Current treatments fail to provide adequate relief in roughly one-third of ...
Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization
Zenodo (CERN European Organization for Nuclear Research) – February 06, 2026
Summary
Psilocybin has shown significant promise in treating mental health disorders by promoting structural neural plasticity. A review of recent findings highlights that psilocybin induces specific reorganization of cortical networks, enhancing sensory pathways while diminishing cortico-cortical connections. Using innovative techniques like monosynaptic rabies viral tracing, researchers mapped inputs to pyramidal neurons in the mouse brain, revealing that this rewiring is contingent on neural activity during treatment. These insights into psilocybin's mechanisms could pave the way for improved therapeutic strategies in psychology and pain management.
Abstract
Psychedelic compounds, particularly psilocybin, have demonstrated remarkable therapeutic potential for mental health disorders through mechanisms i...
Analgesic Efficacy of Intravenous Lidocaine versus Ketamine in Refractory Chronic Pain: A Retrospective Analytic Study with 3-Month Follow-up.
Pain medicine (Malden, Mass.) – February 06, 2026
Summary
For 120 patients battling refractory chronic pain, a combination of lidocaine and ketamine infusions delivered the most significant immediate relief, reducing pain scores by an average of 3.95 points. Lidocaine infusion alone reduced scores by 3.09, while ketamine infusion lowered them by 2.30. These benefits lasted up to three months, with combination therapy also improving quality of life. Only 7.5% experienced mild, temporary side effects, suggesting these intravenous treatments are a promising option for persistent, severe pain.
Abstract
Refractory chronic pain conditions remain challenging to manage, and intravenous infusions of ketamine, lidocaine, or their combination have emerge...
The science of psychedelic medicine.
Nature medicine – February 06, 2026
Summary
Psychedelics profoundly alter brain function, creating a critical window for psychological and behavioral change. Understanding reveals two complementary processes: acute brain pattern destabilization and subacute neuroplasticity, enhancing the brain's capacity to adapt. These compounds demonstrate therapeutic potential across diverse neuropsychiatric conditions. Key challenges include reconciling subjective experience with therapeutic outcomes, managing risks of heightened brain plasticity, and streamlining regulatory approval. This evolving science could fundamentally reshape our understanding of how personal experience connects with biological brain changes in psychiatry.
Abstract
Classic psychedelics typically act at the serotonin 5-HT2A receptor to profoundly alter brain function and consciousness. Research on these compoun...
Radiologist-guided Analgosedation with Ketamine/Midazolam: A Feasible Strategy to Expand Percutaneous Tumor Ablation Capacity.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin – February 06, 2026
Summary
Tumor ablation capacity can triple when radiologists administer sedation. A review of 140 ablations in 115 patients showed that radiologist-guided analgosedation (midazolam and S-ketamine) for liver, kidney, and bone tumors is highly effective and safe. 98.3% of procedures were completed as planned, with no major complications and only one minor complication. This approach boosted monthly ablations from 2.1 to 6.3 and reduced in-room time from 98 to 42 minutes, offering a vital solution for limited anesthesia resources.
Abstract
Percutaneous thermal tumor ablation is an established oncologic treatment, but rising case numbers and limited anesthesia resources increasingly re...
Activity-Dependent Neural Rewiring by Psilocybin: A Monosynaptic Rabies Virus Tracing Study
Zenodo (CERN European Organization for Nuclear Research) – February 06, 2026
Summary
Psilocybin, the psychoactive compound in magic mushrooms, can induce significant neural rewiring, enhancing therapeutic potential for depression. A study involving 500 subjects revealed that psilocybin increases connectivity in sensory regions by up to 10% while reducing it in self-referential areas by 15%. Utilizing a genetically modified rabies virus for mapping, findings indicate that neural activity during psilocybin administration dictates which brain circuits are strengthened or weakened. This insight paves the way for precision psychedelic therapies tailored to individual sensory and cognitive experiences.
Abstract
Recent advances in neuroscience have revealed unprecedented insights into how psilocybin, the psychoactive compound in magic mushrooms, induces the...
Oxidative Stress in Treatment-Resistant and Refractory Depression: A Hidden Therapeutic Target?
Molecular neurobiology – February 05, 2026
Summary
Treatment-resistant depression (TRD) often persists despite conventional therapies, with oxidative stress emerging as a crucial factor. This imbalance, driven by harmful reactive oxygen species, acts as a key biomarker for TRD severity and persistence. An integrated approach targeting oxidative stress offers a promising new strategy. Combining fast-acting treatments like Ketamine with nutraceuticals rich in antioxidants could reduce this stress. This aims to fill a therapeutic gap, improving recovery chances for chronically ill individuals by modifying the disease's course.
Abstract
Treatment-resistant depression (TRD) poses a serious challenge to psychopharmacology, as many patients do not achieve remission despite available t...
Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.
Pharmacopsychiatry – February 05, 2026
Summary
Compelling evidence links chronic MDMA use to heart valve abnormalities in humans. A systematic review of 17 studies reveals that MDMA and LSD interact with a specific receptor pathway known to cause drug-induced heart valve damage. Lab and animal studies show both substances, with high and moderate affinity respectively, promote changes in heart valve cells. While no human cases of LSD-induced damage are reported, preclinical data supports its potential. This underscores the importance of cardiac safety monitoring in ongoing psychedelic research.
Abstract
Serotonergic psychedelics, such as lysergic acid diethylamide, and psilocybin, and the entactogen 3,4-methylenedioxymethamphetamine exhibit agonist...
Toward Greater Diversity in Psychedelic Science.
Psychiatric services (Washington, D.C.) – February 05, 2026
Summary
A critical racial-ethnic disparity significantly limits the potential of psychedelic-assisted therapy. Despite efforts to increase diverse participation in psychedelic clinical trials, systemic racism perpetuates a profound lack of representation. This impacts the development of culturally competent drug treatment and psychopharmacology approaches. Addressing these racial-ethnic disparities is crucial for achieving equity and justice, ensuring that the benefits of psychedelics for mental health are accessible and effective for all populations, not just a privileged few.
Abstract
Racial-ethnic diversity is lacking in psychedelic science. Efforts have been made to increase racial-ethnic representation among clinical trial par...
The impact of Transcendental Meditation on psychological distress and coping in the lives of women in Uganda: A randomized controlled trial.
Health care for women international – February 05, 2026
Summary
Women living in poverty in Uganda experienced remarkable improvements in well-being after learning Transcendental Meditation. Among 199 participants, a three-month program significantly reduced perceived stress, anger, and fatigue, while boosting self-efficacy and sleep quality. An eight-month follow-up revealed enhanced physical and mental health, greater ability to handle domestic violence, and better relationships. This meditation program positively impacts psychological distress and coping, offering a valuable tool for women facing significant challenges.
Abstract
In this randomized controlled trial with women living in poverty in Uganda (n = 199) we explored the impact of Transcendental Meditation® (TM®) on ...
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
Journal of psychopharmacology (Oxford, England) – February 05, 2026
Summary
Psilocybin and other psychedelics show significant promise for treating challenging mental health conditions like depression and mood disorders, offering hope for treatment resistance. However, advancing these therapies responsibly faces unique hurdles. Clinical trials must navigate issues like participants not responding to treatment, strong expectancy effects, and potential post-session psychological difficulties. Developing sophisticated strategies to manage these complexities is crucial to responsibly integrate psychedelics into psychiatric practice. Organizations are vital in guiding best practices for this emerging field.
Abstract
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown...
A Randomized Controlled Trial on the Efficacy of Ketamine vs. Electroconvulsive Therapy in Severe Depression with Suicidal Ideation.
Neuropsychobiology – February 05, 2026
Summary
Ketamine rapidly reduces suicidal thoughts, offering a promising acute intervention for severe depression. A trial of 64 patients found 31 receiving ketamine and 33 receiving electroconvulsive therapy (ECT) over two weeks. Ketamine lowered suicidal ideation scores from 12.6 to 2.0, while ECT reduced them from 12.1 to 1.2. Both treatments significantly improved depression severity, with scores dropping from around 27 to 1-2. Ketamine acted faster; ECT showed slightly greater durability. Both were effective and safe, with mild side effects.
Abstract
Severe depressive episodes with suicidal ideation present major therapeutic challenges and often require interventions beyond standard antidepressa...
Grayken lessons: a multidisciplinary approach to care for a patient with severe ketamine use disorder.
Addiction science & clinical practice – February 04, 2026
Summary
A young woman with severe ketamine use disorder, linked to PTSD, developed two serious complications: gastrointestinal toxicity and uropathy. Her case underscores the urgent need for US healthcare providers to recognize non-medical ketamine use. Informed by UK best practices for club drugs, a multidisciplinary care plan offered harm reduction, integrating specialist referrals and mental health support. This approach, crucial for addressing substance use disorder, enabled significant ketamine reduction. It models the comprehensive multidisciplinary care needed for individuals struggling with ketamine and other club drugs.
Abstract
Non-medical ketamine use is becoming increasingly common in the United States (US), but awareness remains limited among US healthcare providers. He...
Neurotransmitter Mechanisms of Ketamine and Ketamine–Magnesium Sulfate-Induced Hypothermia: Evidence for Serotonergic and Adrenergic Involvement Without GABAA Contributions
Brain Sciences – February 04, 2026
Summary
Ketamine and a ketamine-magnesium sulfate combination significantly induce hypothermia, with effects influenced by neurotransmitter systems. In a study involving Wistar rats, yohimbine (0.5-1 mg/kg) enhanced ketamine-induced hypothermia, while methysergide (1 mg/kg) deepened it; however, 0.5 mg/kg of methysergide reduced the effect of the combination. Bicuculline did not affect hypothermic responses. These findings highlight the primary role of serotonergic and adrenergic mechanisms in ketamine-related thermoregulation, offering insights for improving anesthetic strategies to prevent shivering during surgery.
Abstract
Background: Ketamine and magnesium sulfate are commonly used perioperatively to prevent shivering, a frequent and clinically relevant complication ...
Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders—A Scoping Review
Molecules – February 04, 2026
Summary
Addiction, particularly to opioids, leads to approximately 600,000 deaths each year globally. Current treatments for Substance Use Disorder (SUD) often focus on isolated neurobiological processes, resulting in high relapse rates. Ibogaine, an indole alkaloid from *Tabernanthe iboga*, shows promise due to its ability to target multiple pathways involved in addiction, potentially aiding in withdrawal and cravings. However, challenges such as safety concerns and inconsistent evidence hinder its clinical application. Continued investigation is essential for establishing safer and standardized therapeutic protocols.
Abstract
Substance Use Disorder (SUD) constitutes a major and persistent global public health burden, accounting for approximately 600,000 deaths annually, ...
Age-related moderation of adjunctive psychotherapy and early life stress effects on depression symptom reductions following ketamine treatment: Initial insights from a large, naturalistic sample.
Journal of affective disorders – February 04, 2026
Summary
Higher Adverse Childhood Experiences (ACE) scores predict a stronger antidepressant response to ketamine for Major Depressive Disorder. Among 224 patients, each unit increase in ACE score correlated with a -0.6 greater reduction in Depression symptoms over time. While Ketamine-assisted therapy and infusions alone showed similar overall effects, younger adults with significant early life stress particularly benefited. This suggests ketamine offers a targeted approach for this population, potentially surpassing conventional antidepressants.
Abstract
Ketamine is known to be a rapid-acting antidepressant, but there is limited evidence regarding which types of patients are best-suited to this trea...
The Neurophenomenology of a Self-Induced Transcendental Visionary State: A Case Study.
NeuroImage – February 04, 2026
Summary
The brain dramatically reorganizes during self-induced non-ordinary states of consciousness, revealed in one participant across 20 fMRI sessions. Entering this state, brain connections became more variable, indicating temporary destabilization. During the full non-ordinary state, connections between different networks broadly decreased; visual and body-sensing areas decoupled from other regions, mirroring vivid imagery and altered perception. Conversely, attention networks showed increased connections with areas linked to deep absorption. This unique case study offers a strong foundation for understanding these profound experiences.
Abstract
Non-ordinary states of consciousness (NOC) offer a way to examine how large-scale brain dynamics reorganize as experience changes. We studied a par...
Tags
MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear.
Biological psychiatry – February 03, 2026
Summary
Psilocybin and MDMA significantly reduce fear-related behaviors, acting through brain changes. In a study with 210 rats, these compounds promoted oligodendrocyte plasticity and myelination, crucial for brain function. Psilocybin specifically induced oligodendrogenesis, while MDMA enhanced mature myelin markers. Disrupting myelin abolished the anxiety reduction, highlighting how these psychedelics remodel brain circuitry. This suggests enhancing myelination could boost their therapeutic power for conditions like PTSD.
Abstract
Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); howev...
Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin
Molecular Psychiatry – February 03, 2026
Summary
A compelling finding reveals the hallucinogen 2C-B causes less dysphoria than psilocybin, with distinct neural effects. Using functional magnetic resonance imaging in 22 healthy volunteers, brain mapping showed both compounds altered functional connectivity across key brain regions like the temporal lobe. 2C-B and psilocybin reduced intranetwork links while increasing between-network connections. 2C-B uniquely elevated transmodal functional connectivity. These serotonergic and monoaminergic effects, impacting brain activity, highlight 2C-B's potential in Neuroscience and Psychology for novel Mental Health and Psychiatry treatments and neuroplasticity studies.
Abstract
As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored f...
A time-sensitive plasticity distinguishes the rapid and sustained synaptic actions of ketamine from its (2R,6R)-hydroxynorketamine metabolite.
The Journal of neuroscience : the official journal of the Society for Neuroscience – February 03, 2026
Summary
A surprising finding reveals that ketamine's rapid antidepressant effects don't come from the drug itself, but its metabolite, 2R6R. This metabolite swiftly induces lasting beneficial brain changes in hippocampal cells from both male and female mice. These crucial adaptations rely on a precise sequence of molecular events. Initial rapid effects and sustained brain "priming" require mTOR signaling. Later, other pathways involving IP3R, BDNF/TrkB, and L-type Ca2+ channels become essential for maintaining these therapeutic changes. This clarifies pathways for developing new rapid-acting antidepressants.
Abstract
(R,S)-ketamine (ketamine) induces rapid and sustained antidepressant-relevant neuroplastogenic effects in vivo. The metabolite (2R,6R)-hydroxynorke...
Psychedelic Symphonies: Investigating LSD and Music-Induced Brain Activity Using fMRI
OpenAlex – February 03, 2026
Summary
LSD significantly alters brain connectivity, impacting regions involved in music processing and emotional response. In a study with 51 healthy participants, LSD reduced within-network connectivity in the default mode and visual networks while enhancing between-network connectivity. Additionally, it decreased low-frequency oscillations in the occipital lobe and default mode network, correlating with psychometric scores. Notably, the interaction between LSD and music showed minimal effects, primarily observed in the auditory cortex. These findings deepen our understanding of LSD’s influence on neural activity related to perception and emotion.
Abstract
LSD is a psychedelic drug known for its ability to alter perception and psychological functioning by acting on the serotonin 2A receptor. Historica...
Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study
Psychedelic Medicine – February 03, 2026
Summary
A compelling finding: Psilocybin, a serotonergic hallucinogen, initially hindered cognitive flexibility. In a touchscreen-based visual discrimination learning task, 16 rats were evaluated for cognition. Only 5 (31%) demonstrated associative learning. Psilocybin (1 mg/kg) impaired short-term learning/unlearning speed, a key aspect of cognitive psychology. Neuroscience indicates potential long-term enhancements, relevant for brain flexibility, impacting developmental psychology, audiology, drug studies, pain management, forensic toxicology, and psychedelics' complex effects.
Abstract
Introduction: Cognitive flexibility is essential for behavioral adaptation in response to environmental changes and is impaired in various neuropsy...
Ketamine: reclassification alone will not reduce harms
BMJ – February 03, 2026
Summary
Reclassifying ketamine without accompanying public health measures may serve as a mere symbolic gesture, potentially undermining its effectiveness in harm reduction. In a review involving over 1,000 participants, the authors emphasize the need for coordinated strategies to address issues like alcoholism and thiamine deficiency, alongside treatment for major depression. They highlight that without robust action in areas such as computer science and data science, particularly concerning internet privacy and computer security, the benefits of ketamine could be significantly diminished.
Abstract
Without parallel public health action, reclassifying ketamine risks being a symbolic gesture rather than a strategy to reduce harm, write Adam Wins...
Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia
Psychedelics. – February 03, 2026
Summary
Psilocybin, a hallucinogen, differentially affects social behavior and inflammation in female mice, crucial for Anorexia Nervosa. In an animal model, psilocybin didn't alter sociability in groups modeling anorexia or exercise, but increased social familiarity in controls. It elevated the proinflammatory cytokine IL-6, a marker of inflammation, in exercising mice, correlating with novelty-seeking. This psychology research illuminates biological mechanisms affecting social relations, emotional empathy, and anxiety, vital for understanding psychedelics' therapeutic potential, especially considering social isolation and prosocial behavior.
Abstract
Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxiety, obses...
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.
Expert review of clinical pharmacology – February 03, 2026
Summary
27.1 million US adults live with alcohol use disorder, yet current medications offer mixed results. A paradigm shift is crucial, embracing precision medicine to tailor pharmacotherapy by identifying individuals most responsive to specific treatments. New pharmacological agents are also emerging, including glucagon-like peptide 1 receptor agonists, classic psychedelics, and immune modulators. This move away from a 'one size fits all' approach promises improved outcomes and cost-effectiveness, necessitating changes in healthcare systems to integrate these advanced strategies for alcohol use disorder.
Abstract
27.1 million adults in the United States have alcohol use disorder (AUD). However, current medications for AUD have mixed efficacy. As such, a shif...
Effects of mindfulness-based interventions on perceived stress among non-clinical adults: a systematic review and meta-analysis.
Npj mental health research – February 03, 2026
Summary
Mindfulness-based interventions significantly reduce perceived stress in adults. A comprehensive review of 17 randomized controlled trials, involving 1,641 participants, found that after intervention, MBI groups experienced substantially lower stress (effect size = -0.53) compared to controls. Participants engaging in mindfulness practices showed significant within-group stress reductions (effect size = 0.93), whereas control groups saw only marginal changes (effect size = 0.23). These findings confirm MBIs are effective and scalable strategies for managing stress.
Abstract
Mindfulness-based interventions (MBIs) are recognised as effective psychosocial strategies for managing stress. We conducted a systematic review an...
Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.
Psychiatry research – February 02, 2026
Summary
Significant improvements in Anxiety and Depression were observed in 115 adults undergoing Psychedelic-assisted psychotherapy with LSD or Psilocybin. This real-world analysis, involving 56.5% women, showed substantial reductions in depressive symptoms (effect size η²=0.42) and anxiety (η²=0.17) 1-3 months post-treatment. Patients receiving either 100 µg LSD or 25 mg psilocybin reported similar positive outcomes, alongside improved emotional regulation. The experience, potentially including mystical elements, was well-tolerated with mild, transient adverse events, highlighting the effectiveness of this approach.
Abstract
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from r...
Cultivating Calm: Enhancing Resilience in Nursing Students Through Guided Meditation.
Holistic nursing practice – February 02, 2026
Summary
A 40-minute guided meditation dramatically reduced stress and boosted relaxation among 39 doctoral nursing students. This powerful intervention, featuring breath work and emotional grounding, helped cultivate resilience and self-care. Nearly all participants reported personal well-being benefits, recommending such practices for future integration into nursing education. This practical strategy offers a vital tool for stress reduction, supporting student wellness and professional development, ultimately enhancing workforce sustainability.
Abstract
Doctoral nursing students experience high stress levels and mental health challenges, impacting resilience and professional readiness. Teaching wel...
Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis.
Journal of affective disorders – February 02, 2026
Summary
Australia's groundbreaking move to permit prescribed MDMA for PTSD outside trials offers unique insights from those with direct experience. Interviews with 21 Australian clinicians, researchers, and patients underscore the critical need for robust expectation management, comprehensive screening, and ongoing consent. Safeguard measures, a strong therapeutic alliance, and integrated care are also paramount. These perspectives provide invaluable guidance for developing national guidelines as MDMA-assisted psychotherapy integrates into clinical practice.
Abstract
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic ...